Home » Stocks » FUSN

Fusion Pharmaceuticals, Inc. (FUSN)

Stock Price: $8.21 USD 0.26 (3.27%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Pre-market: $8.85 +0.64 (7.80%) Jul 29, 4:21 AM
Market Cap 345.19M
Revenue (ttm) n/a
Net Income (ttm) -85.64M
Shares Out 42.93M
EPS (ttm) -2.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $8.21
Previous Close $7.95
Change ($) 0.26
Change (%) 3.27%
Day's Open 7.98
Day's Range 7.86 - 8.21
Day's Volume 12,690
52-Week Range 6.61 - 14.31

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HAMILTON, ON and BOSTON, July 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

12 hours ago - PRNewsWire

HAMILTON, Ontario and BOSTON , July 7, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pr...

3 weeks ago - PRNewsWire

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug ...

1 month ago - PRNewsWire

HAMILTON, ON and BOSTON, June 7, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...

1 month ago - PRNewsWire

HAMILTON, ON and BOSTON, June 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...

1 month ago - PRNewsWire

HAMILTON, ON and BOSTON, May 27, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...

2 months ago - PRNewsWire

Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions HAMILTON, ON and B...

2 months ago - PRNewsWire

Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion's lead candidate, FPI-1434, in combination with Merck's Keytruda ...

Other stocks mentioned: MRK
2 months ago - Benzinga

HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...

2 months ago - PRNewsWire

HAMILTON, ON and BOSTON, April 14, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...

3 months ago - PRNewsWire

Product candidate FPI-1434, when administered with olaparib, resulted in enhanced efficacy against colorectal and lung cancer xenografts Combination of IGF-1R targeted alpha therapy with immune checkpoi...

3 months ago - PRNewsWire

HAMILTON, ON and BOSTON, April 1, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

3 months ago - PRNewsWire

HAMILTON, ON and BOSTON, April 1, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

3 months ago - PRNewsWire

- FPI-1434 Phase 1 study is progressing - Recent transactions and partnerships expand and diversify Fusion's pipeline of targeted alpha therapies in development to treat a broad array of tumor types HAM...

4 months ago - PRNewsWire

HAMILTON, ON and BOSTON, Feb. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

5 months ago - PRNewsWire

VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) -- TRIUMF, Canada's particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc...

7 months ago - GlobeNewsWire

Phase 1 Single-Dose Data Show Uptake Across Multiple Tumor Types; No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events HAMILTON, ON and BOSTON, Dec. 10, 2020 /PRNewswire/ -- Fusion Ph...

7 months ago - PRNewsWire

Fusion Pharmaceuticals (FUSN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

HAMILTON, Ontario and BOSTON, Nov. 12, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pr...

8 months ago - PRNewsWire

HAMILTON, ON and BOSTON, Nov. 2, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...

8 months ago - PRNewsWire

Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies Fusion to Host a Conference Call at 8:30am ET...

Other stocks mentioned: AZN
8 months ago - PRNewsWire

HAMILTON, ON and BOSTON, Sept. 29, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...

9 months ago - PRNewsWire

- Following Fusion's June 2020 initial public offering, cash runway extended into 2024 HAMILTON, ON and BOSTON, Aug. 11, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc.

11 months ago - PRNewsWire

HAMILTON, ON and BOSTON, June 25, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

1 year ago - PRNewsWire

The initial public offering of Fusion Pharmaceuticals receiving strong interest from investors as the biotech company increased the deal size. The Fusion Pharmaceuticals IPO trades Friday.

1 year ago - Investors Business Daily

About FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors express... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2020
Stock Exchange
NASDAQ
Ticker Symbol
FUSN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FUSN stock is "Strong Buy." The 12-month stock price forecast is 22.25, which is an increase of 171.01% from the latest price.

Price Target
$22.25
(171.01% upside)
Analyst Consensus: Strong Buy